Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of COVID-19 patients.
The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.
Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.
Chandivali Citizens Announce ‘Shadow Corporator’ To Audit BMC, Monitor Elected Representatives Ahead Of Civic Polls
Mumbai News: BMC Seeks ₹10,900 Crore From State Govt As Liabilities Touch ₹1.93 Lakh Crore
Bombay HC Directs State To Resolve Danda Koliwada Land Dispute, Says Govt Cannot Be ‘Mute Spectator’
Bombay HC Allows Amendments To 1912 Mahalaxmi Temple Trust Scheme, Cautions Against Commercial Exploitation
